Lipidomic Characterization in Non-metastatic Breast Cancer Women Undergoing Surgery: a Pilot Study.

Patients

• Age <65 years (not to have influence on functioning of desaturase enzymes that decline with older ages).
• Neoplastic pathology: primary invasive breast cancer or ductal in situ (DCIS) newly diagnosed, in the pre-operative phase and which has not already undergone chemo- or radiotherapy.
• Absence of serious intestinal and hepatic pathologies, diabetes, both insulin-dependent and in hypoglycaemic treatment or other pancreatic affection, thyroid affections in pharmacological treatment.
• Absence of supplementation with omega-3 based supplements for at least 6 months.
• Homogeneous distribution by BMI (1:1 ratio subjects with BMI≥25 and BMI<25, respectively).
• Informed consent to participate in the study.

controls

• Age <65 years;
• Not be affected by cancer;
• BMI <25kg/m2;
• Informed consent to participate in the study

Exclusion criteria

patients

• Age ≥65 years (would affect the functioning of desaturase enzymes that decline with older age).
• Invasive primary breast cancer or ductal in situ (DCIS) previously treated with chemo- or radiotherapy.
• Metastasis at diagnosis.
• Presence of serious intestinal and hepatic pathologies.
• Presence of diabetes, both insulin-dependent and in hypoglycaemic treatment or other pancreatic disease, thyroid disease in pharmacological treatment.
• Supplementation with omega-3 based supplements for at least 6 months.
• Failure to sign the informed consent to participate in the study.

controls

• Age ≥65 years;
• Suffering from tumor pathology;
• BMI ≥25kg/m2;
• Refusal to sign informed consent to participate in the study.